Q2 2024 EPS Estimates for Henry Schein, Inc. (NASDAQ:HSIC) Boosted by Zacks Research

Henry Schein, Inc. (NASDAQ:HSIC) – Zacks Research increased their Q2 2024 earnings estimates for shares of Henry Schein in a report released on Wednesday, May 1st. Zacks Research analyst U. Biswas now expects that the company will post earnings of $1.27 per share for the quarter, up from their previous estimate of $1.26. The consensus estimate for Henry Schein’s current full-year earnings is $5.07 per share. Zacks Research also issued estimates for Henry Schein’s Q1 2025 earnings at $1.34 EPS.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.04). Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. The business had revenue of $3.02 billion during the quarter, compared to the consensus estimate of $3 billion. During the same period in the previous year, the firm posted $1.21 EPS. The company’s revenue was down 10.5% compared to the same quarter last year.

A number of other research analysts have also recently commented on the stock. Jefferies Financial Group increased their target price on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a report on Wednesday, March 6th. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b-” rating in a research report on Monday, February 26th. Piper Sandler increased their price target on Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a report on Monday, February 26th. Evercore ISI upped their target price on shares of Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a report on Wednesday, February 28th. Finally, SVB Leerink began coverage on shares of Henry Schein in a report on Monday, February 26th. They set a “market perform” rating and a $78.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, Henry Schein currently has a consensus rating of “Hold” and a consensus target price of $81.09.

Henry Schein Price Performance

Henry Schein stock opened at $68.53 on Monday. The firm has a market cap of $8.80 billion, a PE ratio of 21.76, a price-to-earnings-growth ratio of 1.68 and a beta of 0.87. The stock’s fifty day moving average price is $73.22 and its two-hundred day moving average price is $72.32. Henry Schein has a one year low of $60.01 and a one year high of $82.63. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.67 and a quick ratio of 1.00.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now owns 209,562 shares in the company, valued at approximately $15,585,125.94. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the sale, the insider now directly owns 209,562 shares in the company, valued at approximately $15,585,125.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bradford C. Connett sold 6,430 shares of the company’s stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the transaction, the chief executive officer now directly owns 73,108 shares in the company, valued at approximately $5,430,462.24. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Institutional Trading of Henry Schein

Institutional investors and hedge funds have recently made changes to their positions in the stock. McGlone Suttner Wealth Management Inc. purchased a new stake in Henry Schein during the 4th quarter valued at $39,000. Baystate Wealth Management LLC increased its position in Henry Schein by 2,500.0% during the 3rd quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock valued at $39,000 after buying an additional 500 shares in the last quarter. Neo Ivy Capital Management purchased a new position in shares of Henry Schein in the 3rd quarter worth about $46,000. Mather Group LLC. bought a new position in shares of Henry Schein in the first quarter worth approximately $97,000. Finally, Covestor Ltd increased its holdings in shares of Henry Schein by 22.8% in the 3rd quarter. Covestor Ltd now owns 1,367 shares of the company’s stock worth $102,000 after purchasing an additional 254 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.